Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to EverolimusConcetta Sciammarella, Anna Grimaldi, Amalia Luce et al.|Frontiers in Oncology|2020Cited by 22
Abstract C020: First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumorsAlison M. Schram, Howard A. Burris, Abdul Rafeh Naqash et al.|Molecular Cancer Therapeutics|2023Cited by 8
Supplementary Table S3 from Integrated Genomic Characterization of the Human Immunome in CancerYongsheng Li, S. Stephen Yi, Brandon Burgman et al.|Unknown|2023Cited by 0
Supplementary Table S1 from Integrated Genomic Characterization of the Human Immunome in CancerYongsheng Li, S. Stephen Yi, Brandon Burgman et al.|Unknown|2023Cited by 0
Supplementary Table S5 from Integrated Genomic Characterization of the Human Immunome in CancerYongsheng Li, S. Stephen Yi, Brandon Burgman et al.|Unknown|2023Cited by 0